Market Place
Sourcing Support
AstraZeneca Pharma India to launch Tremelimumab
23 Sep 2024 //
INDIANPHARMAPOST
Imfinzi Plus Imjudo Shows 5-Year Survival In Liver Cancer
16 Sep 2024 //
BUSINESSWIRE
IMFINZI Reduces Recurrence Risk In Bladder Cancer In NIAGARA Trial
15 Sep 2024 //
BUSINESSWIRE
AstraZeneca`s Biologic Imjudon (Tremelimumab) Receives Suppl Approvals in US
24 Jul 2024 //
FDA
AstraZeneca`s Biologic Imjudo (tremelimumab) Receives Approval in the U.S.
25 Jan 2024 //
FDA
IMFINZI plus IMJUDO® demonstrated sustained overall survival benefit in ALC
29 Jun 2023 //
BUSINESSWIRE
AstraZeneca`s Biologic Imjudo (Tremelimumab) Receives Approval in the U.S.
14 Jun 2023 //
FDA
CDSCO approves AstraZeneca`s anti-liver cancer drug combination
01 Jun 2023 //
ECONOMIC TIMES
AstraZeneca`s Tremelimumab Receives Approval in Europe
04 Apr 2023 //
EMA
AstraZeneca`s Imjudo (Tremelimumab) Receives Approval in Europe
02 Mar 2023 //
EMA
AstraZeneca`s Imjudo (Tremelimumab) Approved In Europe
02 Mar 2023 //
EMA
Imfinzi plus Imjudo approved in the EU for patients with NSCLC
23 Feb 2023 //
PRESS RELEASE
BMS claims AstraZeneca`s Imjudo violates two Yervoy patents
25 Jan 2023 //
FIERCE PHARMA
Japan’s MHLW approves AstraZeneca’s Imfinzi, Imjudo for liver, lung cancers
29 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
Imfinzi plus Imjudo recommended for approval in EU by CHMP for lung cancers
19 Dec 2022 //
PRESS RELEASE
Imfinzi and Imjudo with chemotherapy approved in the US for patients
12 Nov 2022 //
PRESS RELEASE
AstraZeneca`s Biologic Imjudo (Tremelimumab) Receives Approval in the U.S.
10 Nov 2022 //
FDA
AstraZeneca`s Biologic Imjudo (Tremelimumab) Receives Approval in the U.S.
28 Oct 2022 //
FDA
AstraZeneca`s CTLA-4 drug treme finally snags its first approval
25 Oct 2022 //
FIERCEPHARMA
AstraZeneca`s Biologic Imjudo (Tremelimumab) Receives Approval in the U.S.
21 Oct 2022 //
FDA
Imfinzi & tremelimumab with chemotherapy demonstrated sustained survival MNSCLC
11 Sep 2022 //
PRESS RELEASE
After 18 years in development, AstraZeneca’s CTLA-4 antibody gets the red carpet
26 Apr 2022 //
ENDPTS
AZ finds treme a place alongside Imfinzi in liver cancer
18 Jan 2022 //
FIERCEPHARMA
IMFINZI + Tremelimumab Demonstrated Unprecedented Survival in Liver Cancer
18 Jan 2022 //
BUSINESSWIRE
Imfinzi strikes up I-O`s first bile duct cancer win
26 Oct 2021 //
FIERCEPHARMA
IMFINZI + Tremelimumab Improved OS in HIMALAYA Phase III Trial in Liver Cancer
15 Oct 2021 //
BUSINESSWIRE
Can Libtayo, cheaper Chinese drugs disrupt the PD-1/L1 market?
01 Oct 2021 //
FIERCEPHARMA
Imfinzi, tremelimumab combo boosts survival outcomes for NSCLC patients
09 Sep 2021 //
PRESS RELEASE
IMFINZI, tremelimumab with chemotherapy improved progression survival by 28%
09 Sep 2021 //
BUSINESSWIRE
Has AstraZeneca finally found a place for tremelimumab?
01 Jun 2020 //
FIERCE PHARMA
Imfinzi, tremelimumab combo flunks SCLC trial
18 Mar 2020 //
PHARMATIMES
AstraZeneca`s Imfinzi shows sustained benefit in lung cancer study
18 Mar 2020 //
FIERCE PHARMA
AstraZeneca immunotherapy combination falls short in bladder cancer trial
07 Mar 2020 //
BIOPHARMADIVE
Imfinzi cancer combo falls short in DANUBE trial
07 Mar 2020 //
PHARMA TIMES
